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Abstract
Ever since the 1960s, transsphenoidal surgery has been the modality of choice for treating
Cushing’s disease. Subsequent visualization of the pituitary fossa and sphenoid sinus may be
done either with the operating microscope or with the relatively new endoscope. The
endoscope due to its panoramic view allows greater visualization as compared to the operating
microscope. It confers greater access to the cavernous sinus, sella, suprasellar, and parasellar
regions and accommodates higher magnifications. It is bi-dimensional, however as opposed to
the operating microscope that provides a three-dimensional view and allows greater depth
perception. This article provides a comprehensive review of the advantages and disadvantages
of the endoscope and compares it to the operating microscope. We hope this article will prove
useful to both clinicians and academicians alike in their approach and management of
Cushing’s disease.
Categories: Neurosurgery
Keywords: cushing disease, endoscopic endonasal, trans-sphenoidal surgery, operating microscope
Introduction And Background
Cushing syndrome is defined as a state of prolonged hypercortisolism and its accompanying
manifestations. When attributable to a pituitary origin, typically a pituitary adenoma or rarely a
carcinoma, it is known as Cushing’s disease - named after and first described by Dr. Harvey
Cushing in 1932 [1-4].
Cushing’s disease is the most common cause of endogenous hypercortisolism [4-8]. It is a rare
disorder that has an incidence of 1.2 to 2.4 cases/million/ year [9-10]. Its estimated prevalence
is nearly 40 cases per million [9]. It is associated with considerable morbidity and mortality [3].
Five-year mortality rates are estimated to be 50% [3,10]. Its presenting features and long-term
complications include rapidly increasing weight, truncal obesity, abdominal striations, moon
facies, buffalo hump, proximal myopathy, hypertension, easy bruising, depression, reduced
immunity and metabolic disturbances such as metabolic syndrome, diabetes mellitus, deranged
lipid profiles, and osteoporosis [3-4,6,8,10-13].
The first report on the transsphenoidal route to access the pituitary dates back to 1907 by
Hermann Schloffer, after which further attempts at exploration were abandoned for nearly half
a century [14-15]. It was during the 1960s that the transsphenoidal approach gained popularity
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and became the established treatment of choice for patients with Cushing’s disease [7-8,15-26].
This was due to the introduction of the operating microscope by Jules Hardy [14]. High
remission rates coupled with few complications have encouraged the widespread use of the
transsphenoidal route [8,16,20]. Only exceptionally, a transcranial approach may be needed
[27]. In the 1990s, Jho pioneered an endoscopic transnasal technique that has become an
alternative to the microscopic technique [14].
This article aims to compare the two techniques by summarizing the findings of recent clinical
series published in literature with a special focus on the advantages of the endoscope along
with any shortcomings when compared to the operating microscope. We hope this article will
prove useful to clinicians and academicians alike in their approach and management of
Cushing’s disease.
Review
Traditionally the transseptal/translabial approach with the use of the operating microscope is
the gold standard transsphenoidal approach [8,15,17,20,24]. It is associated with minimal
morbidity and mortality [15]. However, with recent advances, the endoscope has come forward
as an effective tool - one with the potential to perhaps surpassing the use of the microscope to
become the modality of choice in Cushing’s disease [15,20-21,28-32]. Many studies throughout
the literature comment on the endoscope’s ability to achieve better resection rates, lesser
invasiveness, and fewer complications [7,17,20-22]. Advocates of the microscope, however,
criticize its panoramic view for its lack of three-dimensional vision and depth perception, and
the inability to conduct meticulous microsurgical procedures that comes with it [7,19,21].
Others, meanwhile favor the panoramic view as it leads to better visualization of the bony
structures covering the carotid arteries and the optic nerve [6-7, 17-22,24,26,29-30,33-36].
Remission rates, reported in the literature for transsphenoidal surgery for Cushing’s disease
vary between 42% and 95% [21]. The majority of remission rates lie between 70% and 85% with
no significant improvement in the past years [21]. According to Qiao et al, there is no
difference in remission rates between the endoscope and the microscope for Cushing’s disease
[30]. There may be fewer recurrences with the endoscope but this advantage disappears when
follow up time is taken into account [30].
Being a relatively newer innovation, there are only a few reports that look at the efficiency and
prognostics of a purely endoscopic technique for Cushing’s disease. The effectiveness of
pituitary surgery is evaluated by normalization of hormone levels and degree of tumor removal
[15]. At the moment, data suggests that the endoscope is at least equivalent or in some cases
even superior to the operating microscope [15,22]. Please refer to Table 1 for the salient features
including remission rates, recurrences, complications, etc. of clinical series published in the
literature on the use of the endoscope for Cushing’s disease [2,7-9,17-18,21,26,29,32,34].
Paper
Patient
characteristics
Modality Findings Complications
Natea -Maier
et al, 2006 [7]
35 patients (25
females and 10
males). Mean
age of 41.0
±14.8  
Endoscope
The remission rate of 77% after
the first surgery and 83% after
re-operation. The recurrence
rate was 22.8%.
48% of the patients developed
hypopituitarism. Severe epistaxis in
one patient. 3 patients developed
CSF leakage. 3 patients had
polyuria, and 1 developed
hyponatremia. 1 developed mild
hyponatremia. 
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Dehdashti et
al, 2007 [21]
25 patients (19
females and 6
males). Mean
age of 42 ±2.5  
 
Endoscope
The remission rate was 83%.
None of the patients presented
with recurrence at a median
follow up of 17 months.
1 patient had a postoperative CSF
leak. 1 patient developed transitory
DI.
Starke et al,
2012 [34]
61 patients (52
females and 9
males). Mean
age of 49 (14-
63)       
Endoscope
The immediate remission rate of
95%. The remission rate of 84%
in patients with at least one year
follow up. With additional
adjuvant therapy, 94%
successfully achieved remission.
No significant difference in
remission rates between
microadenomas (93%),
macroadenomas (77%) and MRI-
negative Cushing’s (100%).
1 patient had a postoperative CSF
leak. 1 patient presented with
severe epistaxis.  
Smith et al,
2012 [32]
72 patients-
male to female
ratio was 1:3.7.
The median
age of 40 years
(31-50).    
Operating
microscope-
58 patients  
Endoscope-
14 patients
The initial remission rate was 72
%. The recurrence rate was
11%. The median time of
recurrence after initial remission
was 2.1 years. No significant
difference between the operating
microscope and endoscope.
3 patients developed meningitis. 1
patient developed sinusitis
postoperatively. 1 patient had a
septal perforation. 1 patient had a
blocked lacrimal duct. Common
complications seen were transient
DI and postoperative CSF leak.  
Wagenmakers
et al, 2013
[29]
86 patients (72
women and 14
men). Mean
age 42.3 ±14.9
   
Endoscope
Remission rate 60% in MRI-
negative Cushing’s disease, 83%
in microadenomas, 94% in
noninvasive macroadenomas,
and 40% in macroadenomas
invading the cavernous sinus.
The recurrence rate was 16%
after 71+39 months of follow-up.
Postoperative bleeding from the
sphenopalatine artery in 1 patient.
Pulmonary embolism in 1 patient of
persistent Cushing’s disease after
surgery. Postoperative CSF leak in
4 patients. Transient DI in 4
patients. Transient hyponatremia
due to inappropriate ADH secretion
or relative glucocorticoid deficiency
in 10 patients. Infection in 3
patients.  
Berker et al,
2013 [8]
90 patients (79
women and 11
men). Mean
age 38.74 ±
13.01    
Endoscope
Remission achieved in 90 % of
patients (86.9% microadenomas,
96.6% macroadenomas, 95.7%
primary patients, 71.4%
recurrent/ persistent disease.
The recurrence rate was 5.6%.
Reentered remission after
reoperation  
Intraoperative CSF leak in 8
patients. Out of which, 2 had a
postoperative leak as well.
Temporary DI in 7 patients  
Permanent DI in 1 patient.
Postoperative meningitis after two
weeks in 1 patient.
Storr et al
2014 [17]
Six pediatric
patients (5
males and 1
female). Mean
age 14.6
Endoscope
Remission achieved in 83.3% of
the patients. No recurrence at
mean 4.7 years follow up
Intraoperative sinus bleeds in 1
patient. Postoperative CSF leak in 1
patient. Panhypopituitarism in 1
patient. GH and gonadotropin
deficiency in 1 patient.  
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Kuo et al,
2015 [26]
40 patients (38
females and 2
males). Mean
age 41 ± 13    
 
Remission achieved in 72.5%
(81.8% microadenomas, 77.8%
noninvasive macroadenomas,
44.4% macroadenomas that
invaded the cavernous sinus.
Recurrent/ persistent disease in
11 patients  
CSF leak in 5 patients.
Sarkar et al,
2016 [18]
64 patients  
Mean age 31.9
± 9.6    
Endoscope
Remission in 79.7 % of the 59
cases followed up for >3 months
and was superior for
microadenomas (86.4 %) versus
macroadenomas (55.6 %) and
equivocal MRI adenomas (66.7
%).
Postoperative CSF rhinorrhea
occurred in 5 patients. New
endocrine deficits in 17.1 % of
patients.
Cebula et al,
2017 [2]
230 patients.
Mean age of 42
± 13.5 years    
Endoscope
Remission in 79.1% of patients
after a median follow up of 21 ±
19.2 months. The remission rate
was significantly increased for
microadenomas and positive
histology. The recurrence rate of
9.8% with a mean time
32.7±15.2 months.  
Post-operative complication
occurred in 77 patients (35.5%).
Predominant postoperative
complications were transient DI and
intraoperative CSF leakage (22%
and 12.6% respectively). The rate of
long-term DI was 6.4%. Two cases
of transient visual complications
occurred. Four people had epistaxis.
Donofrio et al,
2017 [9]
709 patients
(142 Cushing’s
disease
patients and
299
nonfunctioning
pituitary
adenomas).  
Operating
microscope
A remission rate of 80.3%.
Major complications reported in 7
Cushing’s disease patients (4.9%).
Minor complications reported in 3
Cushing’s disease patients (2.1%).
Postoperative DI reported was
10.6% and isolated hyponatremia
reported was 10.6%. 
TABLE 1: Summary of case series published on endoscopic transsphenoidal
resection of Cushing’s disease that were available on PUBMED as full-text articles
Abbreviations: MRI: magnetic resonance imaging, CSF: cerebrospinal fluid, DI: diabetes insipidus, ADH: antidiuretic
hormone, GH: growth hormone
Operative technique
The procedure is done under general anesthesia. It is conducted in collaboration with an
otolaryngologist. The patient is kept supine with the head maintained in a fixed position using
a three-pin Mayfield clamp. The head of the bed is elevated. Frameless stereotaxy is used for
neuronavigation (Figure 1).
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FIGURE 1: Neuronavigational planning of endoscopic
transsphenoidal surgery in a patient with Cushing's disease.
(A) T1 with contrast, coronal section. (B) T1 with contrast, saggital section. (C) T1 with contrast,
axial section. (D) Magnified coronal section showing a tumor in sellar region, more on the right side
The different color schemes in the figure hold no significance and are a result of the software used
for neuronavigational planning 
Using the binostril, bimanual technique, the endoscope is inserted and the Hadad flap is raised.
The sphenoid ostium is identified. The posterior septum is removed to expose the vomer. The
sphenoid sinus is identified and the intersinus septum is removed. The anterior part of the sella
is then opened using a drill and Kerrison rongeur.
After identifying the bony landmarks of the optic nerve, carotid artery, and opticocarotid
recess, a disc dissector is used to remove dura from the bone of sella floor. The dura is opened
and separated from the gland underneath using a micro dissector. Care should be taken not to
coagulate dura as this may lead to white discoloration that may hinder tumor identification
[19]. Once the bone has been removed, neuronavigation is used to locate the tumor. Resection
is then carried out using a micro dissector, suction device, and ring curettes of varying
diameters and orientations. The tumor is identified as a discolored gray region upon the
orange-pink coloration of the gland.
The sellar defect is repaired using the Hadad flap followed by fibrin adhesive, Surgicell, and
Gellfoam.
Video 1 reviews the operative technique for endoscopic transsphenoidal surgery.
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VIDEO 1: Endoscopic transsphenoidal removal of Cushing’s
disease. Procedure done by authors AAL and AD. Commentary
by author MZB.
Abbreviations: AAL: Altaf Ali Laghari, AD: Aneela Darbar, MZB: Mirza Zain Baig
View video here: https://www.youtube.com/watch?v=wDN7gR9WzOs&feature=youtu.be
In cases of negative magnetic resonance imaging (MRI), inferior petrosal sinus sampling (IPSS)
is done to determine the lateralization of the disease. A selective adenectomy is done in cases
where the tumor is identified on surgical exploration. Otherwise, subtotal hypophysectomy is
done on the side of IPSS lateralization. Refer to Figure 2 for a summary of the workup done for
Cushing’s syndrome.
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FIGURE 2: Diagnostic workup of Cushing’s syndrome
Abbreviations: ACTH: adrenocorticotropic hormone; MRI: magnetic resonance
imaging; ETSS: endoscopic transsphenoidal surgery; IPSS: inferior petrosal sinus sampling
Advantages of the endoscope
The hallmark feature of endoscopic transsphenoidal surgery is the superior view one has of the
sphenoid sinus and the pituitary fossa [7-8,13,15,17,20,22,30,34,36]. It gives greater lighting
hence contributing to the better visualization and - depending on the scope used - an ability to
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operate at an angle [7-8,13,15,21,30]. Its panoramic vision allows greater exploration of the
sella, suprasellar, and parasellar regions including the cavernous sinus area - as opposed to the
traditional microscope that allows visualization only in a straight line between the scope and
the pathology being observed [7-8,13,15,20-22,30,34]. This means that the surgeon can now
visualize tumors superiorly at the base of the third ventricle, inferiorly to the lower clivus, and
laterally to the carotids and the cavernous [15]. The endoscope also allows higher
magnifications, which make it an excellent choice for patients with Cushing’s disease which are
typically small tumors.
Another significant advantage of the endoscope is that it allows the surgeon greater access to
the cavernous sinus [30,35]. Previously tumor invasion of the cavernous sinus was considered a
negative prognosticator and an absolute contradiction to surgery [35]. It has been rightfully
called the anatomic jewel box by Parkinson due to the density of neurovascular structures
within its dural walls [25]. With the development of the endoscope, however, this is no longer
the case and tumors reaching into the cavernous sinus can be successfully operated on and
removed using a 30-degree scope [35].
Since the endoscopic approach does not utilize transseptal dissection, there is less post-
operative pain and discomfort [7-8,17]. Hospital stays are shorter with fewer complications [7-
8,17,22]. In particular, there are decreased incidences of septal perforation, epistaxis, and
transient Diabetes Insipidus (DI) with the endoscopic technique [8,13,22]. This leads to greater
patient satisfaction scores. It is because of these reasons and the fact that it causes minimal
skull base trauma that Storr et al [17] emphasize the use of endonasal endoscopic
transsphenoidal surgery in pediatric age groups. In their case series, Storr et al. also report
fewer PICU admissions and blood transfusions. Also, being minimally invasive, reoperation,
when needed, is much simpler as compared to the microscope which unfortunately brings
about a greater distortion of normal anatomy [8,22]. Additionally, the wider field of vision of
the endoscope serves helpful during reoperation when normal anatomical landmarks have been
disrupted [17,19,22].
Disadvantages of the endoscope
The operating microscope resorts to its three-dimensional vision and depth perception, giving
the surgeon the ability to operate in three-dimensional space - a feature that is, unfortunately,
missing in the endoscope [7-8,20,30]. The endoscope is bidimensional and hence does now
provide any depth perception [7,20-21,30]. This is by far the biggest disadvantage of the
endoscope as the lack of stereoscopic vision makes it difficult to discriminate adenomas from
surrounding hypophyseal tissue [13]. Although 3D endoscopes have been developed and are
available in the market to address this issue, their widespread adaptation and the subsequent
results remain to be seen in future literature [30]. There is also the difficulty of manipulating
tools through a narrow corridor [8,21]. However, both these issues can be overcome with
surgeon experience [8,21]. Using a binostril, bimanual technique may also address this [8,21].
The learning curve involved in endoscopic transsphenoidal surgery has been investigated in the
series by Chao-Hung et al. where the authors stratified their patients temporally and reported
greater recurrences in earlier cases [26]. This corroborates the presence of a learning curve in
endoscopic transsphenoidal surgeries that required experience and training to be acquired
[13,26].
Concerns have also been raised regarding its lack of maneuverability as surgeons can only
manipulate tools with one hand unless a holder is used [7]. The use of an assistant may,
however, crowd the operative field [7].
Another disadvantage that has been reported is the increased incidence of extracranial
manifestations [20]. These include nasal crusting and synechiae formation [20]. This may be a
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direct result of the repetitive passage of instruments in the nasal cavity [20]. Postoperative
nasal debridement is usually required [20]. 
There is also increased incidences of vascular complications and post-operative cerebrospinal
fluid (CSF) leaks with the endoscope [13]. The increase in vascular complications may be
attributed to the fact that the surgeon may attempt more radical tumor excision with the
endoscope by virtue of the increased view.
Systemic review and meta-analysis
In our review of the literature, we found several systemic reviews and metanalysis that
compared microscopic and endoscopic surgical techniques and prognostics in a heterogeneous
population of patients with various pituitary adenomas [15,20,22,28]. We found two studies
that were accessible as full-text articles that compared the two surgical techniques in the
setting of Cushing’s disease only [13,30]. The findings of all these studies are summarized in
Table 2 [13,15,20,22,28,30].
Paper
Number of
studies
and
patients
assessed
Findings
Rotenburg
et al, 2010
[28].
11 studies
Fewer complication rates in endoscopic surgeries. Differences in septal perforations were
found to be insignificant in three studies. Decreased operating times, lumbar drains,
immediate postoperative DI, rhinologic complications, length of hospital stay, and pain in
endoscopic approach. Degree of tumor resection and change in post-operative hormone
levels comparable in both techniques.   
Goudakos
et al, 2011
[15].
11 studies  
806 patients
(369 had
endoscopic
surgery and
437 had
microscopic
surgery)
66% remission rate in the endoscopic group versus 60% in the microscopic group. Degree of
tumor resection comparable in both techniques. No significant difference between the rates of
CSF leaks between the endoscope (19.5%) and the microscope (14.4%). Significantly shorter
hospital stays with the endoscopic technique (3.7 – 4.4 days) versus microscopic technique
(5.4 – 5.7 days).
Ammirati
et al, 2012
[20].
24 cohort
studies  
1670
patients
(702 had
endoscopic
surgery and
968 had
microscopic
surgery)
Higher rates of vascular complications with the endoscope
21 studies  
  940
patients
Transient DI higher in the endoscopic group (6.3%) versus the microscope (5.0%). No cases
of permanent DI in the endoscopic group, while 2.8% of patients in the microscopic group had
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Esquenazi
et al, 2017
[22].
(292 had
endoscopic
surgery and
648 had
microscopic
surgery)  
permanent DI. Higher rates of postoperative pituitary insufficiency in the endoscopic group
(7.9%) versus microscopic group (5.2%) Higher rates of cranial nerve palsy in endoscopic
surgery (1.4%) than in microscopic surgery (0.8%). Higher rates of CSF leaks in the
endoscopic group (4.4%) versus in the microscopic group (2.1%). No mortality in the
endoscopic group whereas 7 people died in microscopic with a pooled proportion of 1.5%.
Broerson
et al, 2018
[13].  
97 studies
6695
patients
(984 had
endoscopic
surgery and
5711 had
microscopic
surgery)  
Similar remission rates (80%) for both techniques. Hydrocortisone dependency was seen in
39.3% patients in microscopic surgery and 33.5% after endoscopic surgery. Similar
recurrence rates (10%) for both techniques. Fewer rates of CSF leaks with microscopic
surgery (4.0%) than in endoscopic surgery (12.9%). SIADH, bleeding and permanent DI were
seen slightly less often in patients after microscopic surgery, than in patients after endoscopic
surgery. Transient DI was reported more often in patients after microscopic surgery (21.7%)
than in endoscopic surgery (11.3%). Recurrence rates 17.0 % after microsurgery and 1.5%
after endoscopic surgery.
N Qiao,
2018 [30].
24 studies  
1670
patients
(702
patients had
endoscopic
surgery and
968
microscopic
surgery)
No significant difference in remission rates between endoscopic surgery (79.7%) and
microscopic surgery (76.9%). Recurrence rates for endoscopic surgery were 11.0% and for
microsurgery, 15.9% Proportion of remission in micro-adenomas was statistically significantly
higher in the endoscopic group (87.3%) than in the microscopic group (79.3%).  
TABLE 2: Summary of systemic reviews and metanalysis published on endoscopic
versus microscopic transsphenoidal resection of Pituitary adenomas that were
available on PUBMED as full-text articles
Abbreviations: DI: Diabetes Insipidus, CSF: cerebrospinal fluid, SIADH: syndrome of inappropriate antidiuretic hormone
Conclusions
According to the literature published to date, an endoscope is an effective tool in
transsphenoidal surgeries. Its superior view along with better patient prognostics establish it as
a superior modality for Cushing’s disease when compared with the microscope. Significant
limitations need to be considered, however, as there exists a learning curve for surgeons using
the endoscope. Lack of maneuverability and extra-cranial complications need to be addressed
as well. In the future, 3D endoscopes may perhaps become a mainstream modality. The
operative microscope can till then be utilized upon the surgeon’s discretion.
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